Competition In TSLP TherapiesThe TSLP-targeted therapy space continues to see active transactions, indicating growing momentum in this area.
Net LossThe Company narrowed its net loss significantly to RMB 266.8mn, an improvement from RMB 574.1mn in 2023, as revenue growth outpaced cost expansion.
R&D ChallengesGlobally, the development of TSLP-targeted therapies is accelerating following the approval of tezepelumab for asthma.